Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients.

Lourdes Mengual Maria FrantziMarika MokouMercedes Ingelmo-TorresMichiel VlamingAxel S MerseburgerMarie C RoeschZoran CuligAntonio AlcarazAntonia VlahouHarald MischakAntoine G Van der Heijden

Published in: British journal of cancer (2022)

BC-116 biomarker panel is a useful test for detecting primary BC. BC-106 classifier integrated with cytology showing >95% negative predictive value, might be useful for decreasing the number of cystoscopies during surveillance.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
public health
peritoneal dialysis
prognostic factors
high grade
patient reported outcomes
fine needle aspiration